New strategies for applying targeted therapies to adrenocortical carcinoma.
Ontology highlight
ABSTRACT: Adrenocortical carcinoma (ACC) is a rare, aggressive, and frequently deadly cancer. Up to 75% of all patients will eventually develop metastatic disease, and our current medical therapies for ACC provide limited - if any - survival benefit. These statistics highlight a crucial need for novel approaches. Recent studies performing comprehensive molecular profiling on ACC have illuminated that ACC is comprised of three clinically distinct molecular subtypes, bearing differential regulation of cell cycle, epigenetics, Wnt/β-catenin signaling, PKA signaling, steroidogenesis and immune cell biology. Furthermore, these studies have spurred the development of molecular subtype-based biomarkers, contextualized outcomes of recent clinical trials, and advanced our understanding of the underlying biol
SUBMITTER: Mohan DR
PROVIDER: S-EPMC7133705 | biostudies-literature | 2019 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA